A randomized, double-blind, placebo-controlled, phase II clinical trial to investigate the efficacy and safety of oral DA-1229 in patients with type 2 diabetes mellitus who have inadequate glycaemic control with diet and exercise

BACKGROUND: DA-1229 is a novel, potent and selective dipeptidyl peptidase-4 (DPP-IV) inhibitor that is orally bioavailable. We aimed to evaluate the optimal dose, efficacy and safety of DA-1229, in Korean subjects with type 2 diabetes mellitus suboptimally controlled with diet and exercise. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Jung, Chang Hee, Park, Cheol-Young, Ahn, Kyu-Joeng, Kim, Nan-Hee, Jang, Hak-Chul, Lee, Moon-Kyu, Park, Joong-Yeol, Chung, Choon-Hee, Min, Kyung-Wan, Sung, Yeon-Ah, Park, Jeong-Hyun, Kim, Sung Jin, Lee, Hyo Jung, Park, Sung-Woo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2015
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4670720/
https://www.ncbi.nlm.nih.gov/pubmed/25362864
http://dx.doi.org/10.1002/dmrr.2613

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4670720/
https://www.ncbi.nlm.nih.gov/pubmed/25362864
http://dx.doi.org/10.1002/dmrr.2613

Ejemplares similares